SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense volatility after disclosing that Marvell canceled its purchase orders due to a confidentiality breach, sparking widespread community debate over management's transparency and potential legal risks. While some investors view the significant price dip as a long-term buying opportunity for the company's optical technology, others are bracing for further downside amid concerns regarding lost credibility and potential class-action litigation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is seeing significant bullish momentum as it nears record highs, fueled by intense investor interest in the ongoing AI infrastructure build-out and sustained institutional demand. The community is actively debating the stock's valuation and long-term trajectory, with many focusing on its critical role as the primary enabler of the AI revolution despite broader market volatility and geopolitical concerns.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as investors debate whether the stock is a legitimate growth opportunity following recent revenue surges and strategic appointments or a high-risk "pump and dump" scheme. The community remains sharply divided, with some betting on a potential short squeeze while others warn of delisting risks and aggressive volatility typical of micro-cap stocks.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant momentum as investors bet on the company's critical role in the AI data center supercycle, fueled by a combination of positive analyst sentiment and anticipation surrounding upcoming earnings. The community remains highly polarized, with intense debates over the sustainability of its parabolic rally, the potential for a stock split, and whether the stock's valuation is driven by genuine AI-demand or speculative exhaustion.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following a significant rally driven by a new multibillion-dollar share buyback authorization and a dividend increase, which have boosted investor sentiment. The community is actively debating the stock's long-term potential in AI and edge computing versus concerns about handset market headwinds and competitive pressures.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing a surge in volume and price momentum driven by strong institutional accumulation, including significant insider purchases and stake reports from major funds. Investors are closely tracking the company's progress toward upcoming clinical data presentations and potential regulatory milestones, fueling speculation about long-term valuation and strategic partnerships.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as the community debates the significance of its Phase 3 HAE data against the backdrop of significant short interest. Discussions are split between those anticipating a major squeeze driven by fundamental validation of its gene-editing platform and skeptics wary of commercialization hurdles, dilution risks from the company's ATM program, and strong competition in the sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing significant market volatility driven by the registration of millions of shares tied to CEO Elon Musk's compensation package and ongoing debates regarding the company's autonomous driving strategy. Investors remain sharply divided, with bulls pointing to long-term AI and robotics potential, while bears focus on margin pressures and a narrative they argue has detached from current delivery and growth fundamentals.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Inc

Coeptis Therapeutics is trending as investors anticipate the upcoming merger with Z Squared and a subsequent ticker change, with community members actively discussing the potential value of the spinoff and mining operations. Despite volatility and speculation regarding the timing of the deal, traders are closely monitoring volume spikes and short interest as they look for a breakout catalyst.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending following a 175 million dollar underwritten offering aimed at funding its Phase 3 acne trial and advancing its pipeline, driving significant debate among investors about the dilution impact versus the potential for long-term growth. While the stock has seen high volume and sharp price swings, the community remains divided, with some traders targeting technical breakout levels while long-term investors highlight the asset's de-risking as a potential catalyst for future partnerships or acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
